Taken together, Cdc42-inhibitors (possibly in combination with anti-angiogenic drugs) may prove therapeutically beneficial not only against primary and recurrent glioblastoma, but also other tumors that co-opt blood vessels during brain metastasis [57]. The gene discussed is CDC42; the disease is glioblastoma.